Sugar substance kills good cholesterol
Scientists at the University of Warwick have discovered that ‘good’ cholesterol is turned ‘bad’ by a sugar-derived substance.
The substance, methylglyoxal - MG, was found to damage ‘good’ HDL cholesterol, which removes excess levels of bad cholesterol from the body.
Low levels of HDL, High Density Lipoprotein, are closely linked to heart disease, with increased levels of MG being common in the elderly and those with diabetes or kidney problems.
Supported by funding from the British Heart Foundation (BHF) and published in Nutrition and Diabetes, the researchers discovered that MG destabilises HDL and causes it to lose the properties which protect against heart disease.
HDL damaged by MG is rapidly cleared from the blood, reducing its HDL content, or remains in plasma having lost its beneficial function.
Lead researcher Dr Naila Rabbani, of the Warwick Medical School, says that: “MG damage to HDL is a new and likely important cause of low and dysfunctional HDL, and could count for up to a 9% risk of heart disease”.
There are currently no drugs that can reverse low levels of HDL, but the Warwick researchers argue that by discovering how MG damages HDL has provided new potential strategies for reducing MG levels.
Commenting on the research’s implications Dr Rabbani said:
“By understanding how MG damages HDL we can now focus on developing drugs that reduce the concentration of MG in the blood, but it not only be drugs that can help.
“We could now develop new food supplements that decrease MG by increasing the amount of a protein called glyoxalase 1, or Glo 1, which converts MG to harmless substances.
“This means that in future we have both new drugs and new foods that can help prevent and correct low HDL, all through the control of MG.”
A potentially damaging substance, MG is formed from glucose in the body. It is 20,000 times more reactive than glucose it damages arginine residue (amino acid) in HDL at functionally important site causing the particle to become unstable.
Glo1 converts MG to harmless substances and protects us. MG levels are normally kept low in the body to maintain good health but they slowly increase with ageing as Glo1 slowly becomes worn out and is only slowly replaced.
Dr Rabbani says: “We call abnormally high levels of MG ‘dicarbonyl stress’. This occurs in some diseases – particularly diabetes, kidney dialysis, heart disease and obesity. We need sufficient Glo1 to keep MG low and keep us in good health.”
Dr Shannon Amoils, Senior Research Advisor at the BHF, which funded the study, said:
“Dr Rabbani’s study shows us how the ‘good cholesterol’, HDL, can be damaged by a compound produced by the breakdown of sugar. This compound is increased in the circulation in people with diabetes.
“This interesting finding adds to evidence that under certain conditions, HDL can be modified so that it loses its heart protective effects, and that regarding HDL as ‘good cholesterol’ in all circumstances may be too simplistic.
“If the modified HDL cholesterol that Dr Rabbani is studying is found in large numbers of people with diabetes, the culprit compound that damages it could potentially be targeted with a drug to block its harmful action or to remove it from the circulation.”
2 September 2014
Notes to Editors:
To speak with Dr Rabbani please contact Tom Frew, International Press Officer – University of Warwick; firstname.lastname@example.org +44 (0)2476575910
The British Heart Foundation (BHF)
For over 50 years we’ve pioneered research that’s transformed the lives of people living with heart and circulatory conditions. Our work has been central to the discoveries of vital treatments that are changing the fight against heart disease. But so many people still need our help. From babies born with life-threatening heart problems to the many Mums, Dads and Grandparents who survive a heart attack and endure the daily battles of heart failure. Join our fight for every heartbeat in the UK. Every pound raised, minute of your time and donation to our shops will help make a difference to people’s lives.
For more information visit bhf.org.uk.
For more information please call the BHF press office on 020 7554 0164 or 07764 290 381 (out of hours) or email email@example.com.
To speak with Dr Rabbani please contact Tom Frew, International Press Officer – University of Warwick; a dot t dot frew at warwick dot ac dot uk